Study to Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic Migraine

NCT03700320 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

744

Enrollment

INDUSTRY

Sponsor class

Conditions

Episodic Migraine

Interventions

DRUG: Standard of Care (SOC) Migraine Preventive Medication
DRUG: Atogepant

Sponsor

Allergan